Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

NCT04227990 is registered in ClinicalTrials.gov with BeyondSpring Pharmaceuticals Inc. as lead sponsor.

NCT NCT04227990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04227990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 27, 2017
Completion date
January 3, 2019
Enrollment
115 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced neutropenia